Get the Stockscreener App
137.00
1.74%
-2.43
After Hours:
137.00
Neurocrine Biosciences Inc stock is traded at $137.00, with a volume of 854.52K.
It is down -1.74% in the last 24 hours and down -4.93% over the past month.
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
See More
Previous Close:
$139.43
Open:
$139.8
24h Volume:
854.52K
Relative Volume:
0.96
Market Cap:
$13.59B
Revenue:
$2.41B
Net Income/Loss:
$305.80M
P/E Ratio:
46.44
EPS:
2.95
Net Cash Flow:
$492.20M
1W Performance:
-2.41%
1M Performance:
-4.93%
6M Performance:
+46.92%
1Y Performance:
+22.15%
1-Day Range:
$135.96
$141.14
1-Week Range:
$135.59
$141.36
52-Week Range:
$84.23
$154.61
Neurocrine Biosciences Inc Stock (NBIX) Company Profile
Name
Neurocrine Biosciences Inc
Sector
Phone
(858) 617-7600
Address
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
Compare NBIX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NBIX
Neurocrine Biosciences Inc
|
137.00 | 13.83B | 2.41B | 305.80M | 492.20M | 2.95 |
|
ZTS
Zoetis Inc
|
142.77 | 64.42B | 9.39B | 2.62B | 2.22B | 5.8121 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.46 | 45.95B | 29.96B | 957.25M | 4.77B | 0.2956 |
|
HLN
Haleon Plc Adr
|
8.82 | 39.14B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
20.07 | 22.90B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
456.84 | 20.50B | 3.08B | 1.24B | 1.07B | 25.61 |
Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-21-25 | Initiated | Truist | Buy |
| Jul-10-25 | Initiated | Goldman | Buy |
| Apr-15-25 | Upgrade | Needham | Hold → Buy |
| Apr-14-25 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Feb-11-25 | Initiated | Deutsche Bank | Hold |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Aug-29-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| Apr-24-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Dec-13-23 | Resumed | Citigroup | Neutral |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Oct-24-23 | Resumed | Cantor Fitzgerald | Overweight |
| Aug-21-23 | Reiterated | Mizuho | Neutral |
| Jul-24-23 | Upgrade | SVB Securities | Market Perform → Outperform |
| Jul-06-23 | Upgrade | BMO Capital Markets | Underperform → Market Perform |
| May-04-23 | Upgrade | Guggenheim | Neutral → Buy |
| Mar-30-23 | Upgrade | Canaccord Genuity | Hold → Buy |
| Mar-03-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-03-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-14-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Oct-11-22 | Initiated | UBS | Buy |
| Sep-26-22 | Initiated | Wells Fargo | Equal Weight |
| Jun-06-22 | Resumed | Jefferies | Buy |
| Mar-03-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Feb-25-22 | Upgrade | Goldman | Neutral → Buy |
| Jan-18-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-19-21 | Initiated | BMO Capital Markets | Underperform |
| Nov-17-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-14-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-23-21 | Resumed | Needham | Hold |
| Aug-06-21 | Downgrade | Canaccord Genuity | Buy → Hold |
| May-18-21 | Resumed | Goldman | Neutral |
| May-06-21 | Upgrade | Barclays | Equal Weight → Overweight |
| Feb-02-21 | Initiated | Raymond James | Outperform |
| Sep-30-20 | Initiated | The Benchmark Company | Hold |
| Aug-04-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jun-29-20 | Downgrade | Goldman | Buy → Neutral |
| Jun-09-20 | Initiated | Wedbush | Outperform |
| Mar-06-20 | Initiated | Citigroup | Buy |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-24-20 | Initiated | William Blair | Outperform |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Feb-05-20 | Reiterated | H.C. Wainwright | Buy |
| Dec-13-19 | Downgrade | Credit Suisse | Outperform → Neutral |
| Aug-07-19 | Initiated | RBC Capital Mkts | Outperform |
| Jul-16-19 | Initiated | Oppenheimer | Outperform |
| Jun-05-19 | Initiated | Guggenheim | Neutral |
| May-21-19 | Initiated | Credit Suisse | Outperform |
| Apr-22-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Feb-06-19 | Reiterated | BofA/Merrill | Buy |
| Jan-23-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-13-18 | Initiated | Goldman | Buy |
| Nov-21-18 | Initiated | Canaccord Genuity | Buy |
View All
Neurocrine Biosciences Inc Stock (NBIX) Latest News
Q3 2025 Results: Neurocrine Biosciences to Host Oct. 28 Webcast & Call at 1:30 p.m. PT; Replay 1 Month - Stock Titan
How New Three-Year INGREZZA Data at Neurocrine Biosciences (NBIX) Has Changed Its Investment Story - simplywall.st
A Fresh Look at Neurocrine Biosciences (NBIX) Valuation After Latest INGREZZA Clinical Study Results - Yahoo Finance
Earnings call transcript: Neurocrine Q2 2025 shows strong sales growth By Investing.com - Investing.com Australia
Neurocrine Biosciences names Mike Sibley to lead neuropsychiatry franchise By Investing.com - Investing.com Nigeria
Neurocrine reports sustained benefits of INGREZZA for Huntington’s chorea By Investing.com - Investing.com Nigeria
20+ years commercial leader Mike Sibley named Neurocrine SVP & GM, Neuropsychiatry to lead INGREZZA franchise - Stock Titan
Earnings call transcript: Neurocrine Q2 2025 shows strong sales growth - Investing.com India
Is Neurocrine Biosciences Inc. a candidate for recovery playJuly 2025 Update & Low Drawdown Trading Techniques - newser.com
What MACD signals say about Neurocrine Biosciences Inc.Insider Selling & Smart Allocation Stock Tips - newser.com
Intraday pattern recognizer results for Neurocrine Biosciences Inc.2025 Market Overview & Daily Price Action Insights - newser.com
Neurocrine reports sustained benefits of INGREZZA for Huntington’s chorea - Investing.com
Neurocrine shows 3-year safety data for Huntington's drug INGREZZA - StreetInsider
Neurocrine Biosciences Presents New Three-Year Data Demonstrating Sustained Clinical Benefits and Established Safety Profile of INGREZZA® (valbenazine) Capsules for Huntington's Disease Chorea - PR Newswire
Technical signs of recovery in Neurocrine Biosciences Inc.Weekly Market Report & Risk Controlled Daily Trade Plans - newser.com
Will Neurocrine Biosciences Inc. stock deliver consistent dividends2025 Year in Review & Daily Stock Trend Reports - newser.com
What the G7 Rare Earths News Means for Neurocrine Biosciences Valuation in 2025 - simplywall.st
Will Neurocrine Biosciences Inc. benefit from macro trends2025 Short Interest & Real-Time Volume Triggers - newser.com
Will Neurocrine Biosciences Inc. (NB3) stock see valuation expansionEarnings Summary Report & Free Community Consensus Stock Picks - newser.com
Why Neurocrine Biosciences Inc. (NB3) stock fits value portfolios2025 Market Sentiment & Free High Accuracy Swing Entry Alerts - newser.com
What momentum shifts mean for Neurocrine Biosciences Inc.2025 Valuation Update & Fast Exit/Entry Strategy Plans - newser.com
Is Neurocrine Biosciences Inc. (NB3) stock a buy during volatile marketsFed Meeting & Reliable Price Action Trade Plans - newser.com
Why Neurocrine Biosciences Inc. stock is trending among retail traders2025 Market Outlook & Capital Efficient Trade Techniques - newser.com
Neurocrine (NBIX) Gets a Buy from Bank of America Securities - The Globe and Mail
Neurocrine Biosciences (NBIX): Exploring Valuation After Recent Share Price Movement - simplywall.st
Can Neurocrine Biosciences Inc. stock maintain growth trajectoryPortfolio Update Report & Verified Momentum Stock Alerts - newser.com
Will breakout in Neurocrine Biosciences Inc. lead to full recoveryRate Cut & Safe Entry Point Identification - newser.com
Should I buy Neurocrine Biosciences Inc. (NB3) stock before earnings seasonWeekly Market Report & AI Enhanced Trade Execution Alerts - newser.com
Why Neurocrine Biosciences Inc. stock could benefit from AI revolutionCEO Change & Long-Term Safe Investment Plans - newser.com
Iambic Therapeutics Announces the Addition of Shalini Sharp to its Board of Directors - Business Wire
Neurocrine Biosciences Inc Stock (NBIX) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.86%
0.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):